

**Question for written answer E-006094/2015
to the Commission**
Rule 130
Francesc Gambús (PPE)

Subject: Drugs with cardiovascular risks

After Omeprazole, Paracetamol and acetylsalicylic acid, Ibuprofen is the fourth most consumed medicine in Spain and one of the most common pain-killers in the EU. The Spanish Agency for Medicines and Healthcare Products has recently issued an alert, warning of the risks of suffering a cardiovascular incident if high doses of Ibuprofen are taken. This alert is based on a study carried out by the European Medicines Agency. In the light of this alert, I should like to know:

- What action does the Commission intend to take to rationalise the use of this drug?
- What mechanisms does the European Medicines Agency have at its disposal, within the ambit of its powers, to ensure proper use across the European Union of a medicine about which a Member State has issued an alert?